SCHEMBL276807

SCHEMBL276807

CCCCC(C)(C=O)CC

nearest known ligand 0.36

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
FDPS P14324 1/20 0.32
ADH1B P00325 3/20 0.32
ADH1C P00326 3/20 0.32
ADH1A P07327 3/20 0.32
ADH7 P40394 3/20 0.32
ADH4 P08319 2/20 0.31
EPHX1 P07099 1/20 0.31
ESR1 P03372 1/20 0.30
ESR2 Q92731 1/20 0.30
FAAH O00519 2/20 0.30
TRPV1 Q8NER1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5138900 0.93 TSHR (0.37) TSHRSMN1; SMN2FDPSADH1BADH1C
SCHEMBL6798591 0.91 TSHR (0.41) TSHRFDPSADH1BADH1CADH1A
SCHEMBL6797613 0.91 TSHR (0.41) TSHRFDPSADH1BADH1CADH1A
SCHEMBL6792415 0.91 TSHR (0.41) TSHRFDPSADH1BADH1CADH1A
SCHEMBL6796097 0.91 TSHR (0.41) TSHRFDPSADH1BADH1CADH1A
SCHEMBL6797179 0.91 TSHR (0.41) TSHRFDPSADH1BADH1CADH1A
SCHEMBL9171978 0.90 TSHR (0.39) TSHRSMN1; SMN2FDPSADH1BADH1C
SCHEMBL9245830 0.85 TSHR (0.39) TSHRSMN1; SMN2FDPSADH1BADH1C
SCHEMBL5137670 0.85 TSHR (0.36) TSHRSMN1; SMN2FDPSADH1BADH1C
SCHEMBL2009418 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016038070-A1 COATING COMPOSITION FOR WOOD FINISHING SHERWIN-WILLIAMS DEUTSCHLAND GMBH (DE) 2016-03-17 WO claimed
EP-0018342-B1 NOVEL DERIVATIVES OF GLYCERIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI S.A. (FR) 1983-02-16 EP claimed
CN-106457273-B Flush dispenser for delivering a consistent consumer experience 宝洁公司 2019-05-07 CN disclosed
CN-107921453-A For distributing the distributor of microcapsules 宝洁公司 2018-04-17 CN disclosed
CN-107922882-A Perfume mixture 西姆莱斯股份公司 2018-04-17 CN disclosed
EP-2939996-B1 GROUP 5 METAL OXO-ALKOXO COMPLEX, METHOD FOR PRODUCING SAME, AND METHOD FOR MANUFACTURING GROUP 5 METAL OXIDE FILM TOSOH CORP (JP) 2018-03-21 EP disclosed
CN-107249545-A Composition providing delayed release of active substances 诺赛尔股份有限公司 2017-10-13 CN disclosed
CN-107107019-A It is coated microcapsules 宝洁公司 2017-08-29 CN disclosed
CN-107001979-A Coated microcapsules 宝洁公司 2017-08-01 CN disclosed
CN-106999896-A Coated microcapsules 宝洁公司 2017-08-01 CN disclosed
CN-106999895-A It is coated microcapsules 宝洁公司 2017-08-01 CN disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed
EP-0492847-B2 Air curing polymer composition ROHM & HAAS (US) 2002-11-20 EP disclosed
EP-0381040-B1 METHOD FOR THE PREPARATION OF 2,2-DIALKYLPROPIONALDEHYDES BASF Aktiengesellschaft (DE) 1993-03-31 EP disclosed
US-5012006-A Hydroformylation of 1,1-dialkylethylenes in presence of cobalt carbonyl complex catalysts, water-containing solvents or lactones or sulfones BASF AKTIENGESELLSCHAFT (DE) 1991-04-30 US disclosed
EP-0381040-A2 Method for the preparation of 2,2-dialkylpropionaldehydes BASF Aktiengesellschaft (DE) 1990-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 TSHR 47/4885SMN1; SMN2 2170/4885FDPS 3051/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 TSHR 44/4885SMN1; SMN2 1967/4885FDPS 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.